Last updated: August 1, 2026
Flutamide is an older, generic nonsteroidal antiandrogen used mainly with medical castration for metastatic prostate cancer. Its clinical and commercial relevance has declined because of severe hepatotoxicity, limited use in modern prostate-cancer treatment, and competition from bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone and androgen-deprivation combinations. No active late-stage development program or meaningful branded market remains. Future demand is likely to remain limited to low-cost generic supply and selected off-label use.
What is flutamide and how does it work?
Flutamide is an oral androgen-receptor antagonist. Its active metabolite, 2-hydroxyflutamide, inhibits androgen-receptor signaling and reduces the effect of testosterone and dihydrotestosterone on prostate-cancer cells.
The FDA approved flutamide capsules in 1989 for use with a luteinizing hormone-releasing hormone agonist in patients with metastatic prostate cancer. The combination was intended to reduce the clinical effects of the initial testosterone surge associated with LHRH agonist treatment and to provide combined androgen blockade [1].
Flutamide is usually administered at 250 mg three times daily. The drug is metabolized extensively in the liver, which contributes to its clinically important liver-injury risk [2].
What diseases has flutamide been studied for?
Clinical studies have evaluated flutamide in:
- Metastatic prostate cancer
- Locally advanced prostate cancer
- Nonmetastatic prostate cancer
- Prostate-cancer neoadjuvant therapy
- Female hirsutism
- Hyperandrogenism associated with polycystic ovary syndrome
- Acne and androgen-related dermatologic disorders
- Gender-affirming hormone therapy, generally as an off-label historical use
- Endometriosis and other androgen-sensitive conditions
Its use outside prostate cancer has been constrained by hepatotoxicity. Safer alternatives, including spironolactone, finasteride and newer antiandrogens, have reduced the clinical role of flutamide.
What is the current clinical-trial status of flutamide?
The flutamide clinical-trial record is mature rather than developmental. Registered studies primarily involve completed, terminated or historical prostate-cancer and hyperandrogenism research. There is no established modern Phase 2 or Phase 3 program positioning flutamide as a new treatment for prostate cancer or another major indication.
What did historical prostate-cancer trials show?
Historical trials evaluated flutamide in combination with surgical or medical castration. The main findings were:
- Combined androgen blockade produced greater androgen suppression than castration alone in some studies.
- Overall survival benefits were inconsistent and generally modest.
- Adverse effects included diarrhea, nausea, gynecomastia and liver toxicity.
- Flutamide was later displaced by bicalutamide because bicalutamide offered more convenient dosing and a more favorable tolerability profile.
The European Organisation for Research and Treatment of Cancer and other cooperative groups studied antiandrogen combinations extensively during the 1980s and 1990s. Those studies established the historical role of combined androgen blockade but did not create a durable commercial position for flutamide [3].
Are there active flutamide trials?
The current trial landscape is dominated by legacy records rather than a new development pipeline. Flutamide may appear in observational, pharmacology or combination studies, but the drug does not have the characteristics of an actively sponsored late-stage asset:
| Development indicator |
Current assessment |
| New molecular-entity development |
None |
| Active pivotal prostate-cancer program |
None established |
| New FDA indication program |
None established |
| Large oncology sponsor investment |
Not evident |
| Biosimilar or follow-on biologic program |
Not applicable |
| Main clinical use |
Generic prostate-cancer treatment and limited off-label use |
| Principal clinical barrier |
Severe liver toxicity |
ClinicalTrials.gov remains the principal U.S. registry for identifying registered studies, but trial registration alone does not indicate current commercial development. Historical flutamide records should be separated from actively recruiting studies when assessing pipeline value [4].
What is the FDA regulatory status of flutamide?
Flutamide remains an FDA-approved prescription drug. Its approved use is in combination with an LHRH agonist for metastatic prostate cancer.
The FDA labeling contains a boxed warning for serious, and potentially fatal, liver injury. Liver-function monitoring is required, and treatment should be discontinued in patients with evidence of liver injury or jaundice [1].
What safety issues limit flutamide demand?
The major safety risks are:
- Elevation of serum transaminases
- Clinical hepatitis
- Cholestatic or mixed liver injury
- Rare fatal hepatic failure
- Diarrhea
- Nausea and vomiting
- Hot flashes
- Gynecomastia
- Reduced libido
- Hemolytic anemia in susceptible patients
LiverTox classifies flutamide as a well-established cause of clinically apparent liver injury. The risk is a material disadvantage compared with newer androgen-receptor inhibitors and has restricted use in women with hyperandrogenic disorders [2].
How does flutamide compare with newer antiandrogens?
| Drug |
Mechanism |
Dosing convenience |
Liver-safety profile |
Current market position |
| Flutamide |
Nonsteroidal androgen-receptor antagonist |
Three times daily |
Poor relative profile |
Generic, declining |
| Bicalutamide |
Nonsteroidal androgen-receptor antagonist |
Once daily |
Generally better than flutamide |
Generic, established |
| Enzalutamide |
Potent androgen-receptor signaling inhibitor |
Once daily |
Different safety profile; seizure and fatigue risks |
Branded and generic competition |
| Apalutamide |
Androgen-receptor inhibitor |
Once daily |
Rash, falls and fracture risks |
Branded oncology product |
| Darolutamide |
Androgen-receptor inhibitor |
Twice daily with food |
Lower central nervous system penetration |
Branded oncology product |
| Abiraterone |
CYP17 inhibitor |
Once daily with prednisone |
Mineralocorticoid and hepatic risks |
Major prostate-cancer product |
| Relugolix |
GnRH-receptor antagonist |
Once daily |
Cardiovascular profile differs from LHRH agonists |
Branded oral ADT |
Flutamide has no clear efficacy or convenience advantage against these products. Its remaining competitive attribute is low price.
What patents protect flutamide?
The original flutamide patent estate has expired. Flutamide was discovered and developed decades ago, and its composition-of-matter, original formulation and primary clinical-use exclusivity have lapsed.
When did flutamide lose exclusivity?
The relevant exclusivity periods ended long before the current generic market:
| Exclusivity category |
Status |
| Original compound patent |
Expired |
| Original prostate-cancer use protection |
Expired |
| FDA orphan exclusivity |
Not a current commercial barrier |
| New chemical entity exclusivity |
Expired |
| Generic approval pathway |
Available |
| Current branded monopoly |
None |
No active patent estate is known to create a meaningful U.S. barrier to ordinary flutamide capsules. Any later patents would need to cover a distinct formulation, manufacturing process or narrow method of use. Such patents would not restore broad exclusivity for the conventional 250 mg capsule.
Are there formulation patents covering flutamide?
Flutamide has been studied in modified-release, nanoparticle and combination formulations, but formulation research does not automatically translate into enforceable commercial protection. A formulation patent would need to claim a specific composition and demonstrate practical market relevance.
The standard generic product is an immediate-release oral capsule. The principal competitive barriers are manufacturing quality, supply reliability and regulatory compliance rather than core patent protection.
Does flutamide have Orange Book protection?
Flutamide is listed in FDA-approved drug references and has historically been associated with generic approvals. It does not have the type of current Orange Book patent or regulatory-exclusivity position associated with newer branded prostate-cancer medicines.
An applicant for a generic flutamide product would ordinarily rely on an abbreviated new drug application pathway, subject to applicable bioequivalence and labeling requirements. Paragraph IV litigation risk is low because the original patent barriers have expired.
Are generic companies challenging flutamide patents?
There is no significant current Paragraph IV campaign associated with flutamide. The product is already generic, and the commercial value of challenging a remaining patent would be limited.
Potential suppliers include companies that manufacture generic oncology and cardiovascular products across the United States, India, China and other regulated markets. Supplier activity can change with product discontinuations, facility inspections and contract-manufacturing decisions. No single manufacturer controls the clinical market.
What generic launch risks exist?
A new generic entrant would face commercial rather than intellectual-property risks:
- Low average selling prices.
- Limited unit demand.
- Competition from established generic suppliers.
- FDA compliance requirements for active pharmaceutical ingredient and finished-dose manufacturing.
- Potential supply volatility caused by low margins.
- Demand substitution by bicalutamide and newer prostate-cancer therapies.
A generic launch could be technically straightforward but commercially unattractive unless the entrant has a low-cost supply chain, an existing oncology portfolio or a shortage-driven opportunity.
What is the market size for flutamide?
Flutamide is a mature generic product, and public companies generally do not report it as a separate revenue category. No reliable standalone global sales figure is available from major pharmaceutical disclosures.
The market has three characteristics:
- Low price relative to newer prostate-cancer medicines.
- Low growth because use is being displaced.
- Limited reporting because sales are distributed across generic manufacturers.
What drives remaining demand?
Demand is supported by:
- Low acquisition cost.
- Availability in countries with constrained access to newer antiandrogens.
- Use in selected metastatic prostate-cancer regimens.
- Historical familiarity among prescribers.
- Occasional off-label use where alternatives are unavailable or unaffordable.
Demand is reduced by:
- Hepatotoxicity.
- Three-times-daily administration.
- Inferior tolerability relative to bicalutamide.
- Treatment migration toward abiraterone, enzalutamide, apalutamide and darolutamide.
- Greater use of modern combination regimens.
- Generic price compression.
What is the flutamide market projection through 2030?
Flutamide is more appropriately modeled as a declining maintenance market than as a growth asset. A reasonable commercial scenario is continued unit erosion, with price-driven revenue decline occurring faster than prescription decline.
| Scenario through 2030 |
Unit-volume trend |
Revenue trend |
Primary assumption |
| Base case |
Decline of roughly 5% to 8% annually |
Decline of roughly 7% to 12% annually |
Continued substitution and generic price erosion |
| Downside case |
Decline of roughly 10% to 15% annually |
Decline of roughly 12% to 18% annually |
Faster adoption of newer antiandrogens and supplier exits |
| Stable-access case |
Flat to decline of roughly 3% annually |
Flat to decline of roughly 5% annually |
Persistent use in price-sensitive markets |
These are scenario ranges for strategic planning, not reported market measurements. The base case implies that global flutamide revenue by 2030 would be materially below current levels, while the product would remain available in selected generic markets.
Which regions retain the strongest demand?
The highest residual demand is likely to occur in:
- Lower- and middle-income markets where treatment cost drives prescribing.
- Countries with established generic procurement systems.
- Markets where newer androgen-receptor inhibitors are not reimbursed.
- Regions using older combined androgen-blockade protocols.
Demand in the United States, Western Europe and other high-income markets is likely to remain limited because treatment guidelines and reimbursement increasingly favor newer therapies.
What is the competitive landscape for flutamide?
Flutamide competes in two separate markets.
Prostate-cancer competition
The principal competitors are:
- Bicalutamide and nilutamide among older nonsteroidal antiandrogens.
- Enzalutamide, apalutamide and darolutamide among next-generation androgen-receptor inhibitors.
- Abiraterone among androgen-synthesis inhibitors.
- Docetaxel and cabazitaxel in chemotherapy-based treatment.
- GnRH agonists and antagonists as androgen-deprivation backbones.
Flutamide is generally disadvantaged on efficacy, tolerability, dosing frequency and clinical positioning.
Hyperandrogenism competition
For hirsutism and related disorders, alternatives include:
- Spironolactone
- Finasteride
- Dutasteride
- Cyproterone acetate where available
- Oral contraceptives
- Topical eflornithine
- Laser hair removal and other procedural treatments
Flutamide's liver risk makes it a less attractive option when other therapies are available.
What patent litigation affects flutamide?
No major current U.S. patent litigation appears to define the flutamide market. The product's principal patent disputes, if any, are historical and do not create a current barrier comparable to litigation involving branded prostate-cancer drugs.
There is no meaningful present litigation profile involving:
- A branded flutamide originator defending an active patent estate.
- A major Paragraph IV challenge.
- A patent settlement governing generic entry.
- A biosimilar or interchangeable-product dispute.
The main legal exposure for suppliers is more likely to arise from product liability, manufacturing compliance, labeling and supply obligations than from patent infringement.
How strong is the flutamide patent estate?
The patent estate is weak as a current commercial asset.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Broad therapeutic-use protection |
Expired |
| Current Orange Book leverage |
Low |
| Formulation differentiation |
Limited commercial evidence |
| Manufacturing barriers |
Possible but nonexclusive |
| Freedom-to-operate risk for standard capsules |
Generally low |
| Licensing value |
Minimal |
| Strategic value |
Low-cost generic access only |
Flutamide has no credible patent-based pathway to premium pricing. A company seeking value would need to pursue a differentiated formulation, a new delivery system or a combination product, but the hepatotoxicity problem would remain a substantial development constraint.
Are licensing deals associated with flutamide?
There is no material current licensing market for flutamide. Historical development rights and generic supply arrangements may exist, but the drug is not an active partnering asset for major pharmaceutical companies.
A potential transaction would more likely involve:
- A regional generic commercialization agreement.
- An API supply contract.
- A portfolio acquisition involving several mature products.
- A hospital or government procurement arrangement.
A standalone license for flutamide would have limited strategic value unless linked to an established distribution network or a broader oncology portfolio.
What is the likely generic launch scenario?
The most likely scenario is continued generic availability without a major new entrant. A new supplier could launch if existing manufacturers withdraw, a regional shortage develops or a procurement system seeks a lower-cost source.
The launch would not require a large clinical program. The critical requirements would be:
- FDA-compliant manufacturing.
- Demonstration of bioequivalence.
- Adequate stability data.
- Reliable API sourcing.
- Liver-safety labeling consistent with the reference product.
- Commercial scale sufficient to offset low pricing.
A reformulated flutamide product would face a higher regulatory and reimbursement burden and would need a clear clinical advantage to justify development.
Key Takeaways
- Flutamide remains an FDA-approved generic antiandrogen for metastatic prostate cancer in combination with an LHRH agonist.
- Its clinical-trial record is historical; no significant late-stage development program is established.
- Severe hepatotoxicity is the main medical limitation.
- Original composition, use and exclusivity protections have expired.
- Current Paragraph IV, Orange Book and patent-litigation risk is low.
- The market is mature, fragmented and price-driven.
- Bicalutamide and newer agents have displaced flutamide in most higher-income markets.
- Revenue is likely to decline through 2030, with a base-case annual decline of roughly 7% to 12%.
- The principal commercial opportunity is low-cost generic supply, not branded innovation or licensing.
- Manufacturing quality, supply reliability and regulatory compliance matter more than patent protection.
FAQs
Is flutamide still prescribed for prostate cancer?
Yes. It remains available as a generic option, particularly for androgen blockade and in markets where newer agents are inaccessible. Its use is limited by liver toxicity and competition from better-tolerated therapies.
Can flutamide be used for hirsutism?
Flutamide has been studied and used off-label for hirsutism, but its hepatotoxicity makes it a less attractive choice than spironolactone, finasteride or other alternatives.
Does flutamide have a biosimilar competitor?
No. Flutamide is a small-molecule drug, so the relevant competitive products are generic versions rather than biosimilars.
Is flutamide protected by an active U.S. patent?
The original broad patents have expired. Standard immediate-release flutamide capsules do not have a current patent-based monopoly.
Will flutamide sales grow by 2030?
Growth is unlikely. The more probable outcome is continued unit and revenue decline, driven by generic price erosion and substitution by newer prostate-cancer medicines.
References
-
U.S. Food and Drug Administration. (2024). Flutamide prescribing information. FDA/DailyMed.
-
National Institute of Diabetes and Digestive and Kidney Diseases. (2020). Flutamide. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health.
-
Prostate Cancer Trialists' Collaborative Group. (2000). Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. The Lancet, 355(9214), 1491-1498.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Flutamide studies. National Institutes of Health.
